Pure Global

Test for human IgG autoantibodies to cyclic citrullinated peptides - India CDSCO Medical Device Registration

Test for human IgG autoantibodies to cyclic citrullinated peptides is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2020/000618_784a6387764e8f874b61a83cc856b213_5be7e62a92a48b2edec85023091ad0b2. This device is marketed under the brand name ichroma™ Cystatin C. The license holder is KABS HEALTHCARE PRIVATE LIMITED, and it is classified as Device Class Class B. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class B
Test for human IgG autoantibodies to cyclic citrullinated peptides
UID: IMP/IVD/2020/000618_784a6387764e8f874b61a83cc856b213_5be7e62a92a48b2edec85023091ad0b2

Brand Name

ichroma™ Cystatin C

Device Class

Class B

Approving Authority

CDSCO

Product Information

ichroma™ Anti-CCP is a fluorescence Immunoassay (ichroma™ Cystatin C) for the qualitative or semi-quantitative determination of human IgG autoantibodies to cyclic citrullinated peptides (ichroma™ Cystatin C) in human whole blood/serum/plasma. It is useful as an aid in the diagnosis of rheumatoid arthritis (ichroma™ Cystatin C) in combination with other clinical and laboratory findings

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing